Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADX 097

Next Previous
Drug Profile

ADX 097

Alternative Names: ADX-097

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Q32 Bio
  • Class Anti-inflammatories; Monoclonal antibodies; Peptides; Recombinant fusion proteins; Skin disorder therapies; Urologics
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II IgA nephropathy; Lupus nephritis; Membranoproliferative glomerulonephritis
  • Phase I Skin disorders

Most Recent Events

  • 10 Feb 2025 Q32 Bio discontinues a phase II basket clinical trial in IgA nephropathy, Lupus nephritis and Membranoproliferative glomerulonephritis (Treatment-experienced) in USA (SC, injection) (NCT06419205)
  • 31 Dec 2024 Q32 has patent pending for ADX-097 and the underlying anti-C3d antibodies in PCT and Taiwan
  • 31 Dec 2024 Q32 has patent pending for ADX-097 and the underlying anti-C3d antibodies in USA, Australia, Canada, China, Europe, Hong Kong, India, Indonesia, Israel, Japan, South Korea, Malaysia, Mexico, New Zealand, Philippines, Saudi Arabia, Singapore, South Africa, United Arab Emirates, Qatar, Bahrain, Kuwait, and Oman

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top